Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Beam Therapeutics Inc. before investing.

In this article, we go over a few key elements for understanding Beam Therapeutics Inc.’s stock price such as:

• Beam Therapeutics Inc.’s current stock price and volume
• Why Beam Therapeutics Inc.’s stock price changed recently
• Upgrades and downgrades for BEAM from analysts
• BEAM’s stock price momentum as measured by its relative strength

About Beam Therapeutics Inc. (BEAM)

Before we jump into Beam Therapeutics Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Want to learn more about Beam Therapeutics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Beam Therapeutics Inc..

Beam Therapeutics Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Beam Therapeutics Inc.’s stock price was $25.520.

Beam Therapeutics Inc. is down 3.66% from its previous closing price of $26.490.

During the last market session, Beam Therapeutics Inc.’s stock traded between $25.356 and $26.930. Currently, there are approximately 103.26 million shares outstanding for Beam Therapeutics Inc..

Beam Therapeutics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Beam Therapeutics Inc. Stock Price History

Beam Therapeutics Inc.’s (BEAM) price is currently down 25.64% so far this month.

During the month of July, Beam Therapeutics Inc.’s stock price has reached a high of $38.260 and a low of $24.670.

Over the last year, Beam Therapeutics Inc. has hit prices as high as $38.260 and as low as $15.600. Year to date, Beam Therapeutics Inc.’s stock is down 7.94%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Beam Therapeutics Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Beam Therapeutics Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Beam Therapeutics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Beam Therapeutics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Beam Therapeutics Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Beam Therapeutics Inc. (BEAM) by visiting AAII Stock Evaluator.

Relative Price Strength of Beam Therapeutics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Beam Therapeutics Inc. has a weighted four-quarter relative price strength of -1.31%, which translates to a Momentum Score of 48 and is considered to be Average.

Want to learn more about how Beam Therapeutics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Beam Therapeutics Inc. Stock Price: Bottom Line

As of July 31, 2026, Beam Therapeutics Inc.’s stock price is $25.520, which is down 3.66% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Beam Therapeutics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.